Skip to main content
Article thumbnail
Location of Repository

Integrated Functional, Gene Expression and Genomic Analysis for the Identification of Cancer Targets

By Elizabeth Iorns, Christopher J. Lord, Anita Grigoriadis, Sarah McDonald, Kerry Fenwick, Alan MacKay, Charles A. Mein, Rachael Natrajan, Kay Savage, Narinder Tamber, Jorge S. Reis-Filho, Nicholas C. Turner and Alan Ashworth


The majority of new drug approvals for cancer are based on existing therapeutic targets. One approach to the identification of novel targets is to perform high-throughput RNA interference (RNAi) cellular viability screens. We describe a novel approach combining RNAi screening in multiple cell lines with gene expression and genomic profiling to identify novel cancer targets. We performed parallel RNAi screens in multiple cancer cell lines to identify genes that are essential for viability in some cell lines but not others, suggesting that these genes constitute key drivers of cellular survival in specific cancer cells. This approach was verified by the identification of PIK3CA, silencing of which was selectively lethal to the MCF7 cell line, which harbours an activating oncogenic PIK3CA mutation. We combined our functional RNAi approach with gene expression and genomic analysis, allowing the identification of several novel kinases, including WEE1, that are essential for viability only in cell lines that have an elevated level of expression of this kinase. Furthermore, we identified a subset of breast tumours that highly express WEE1 suggesting that WEE1 could be a novel therapeutic target in breast cancer. In conclusion, this strategy represents a novel and effective strategy for the identification of functionally important therapeutic targets in cancer

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2006). 4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione inhibitors of the checkpoint kinase Wee1. Structure-activity relationships for chromophore modification and phenyl ring substitution.
  2. (2006). A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
  3. (2004). A novel, highperformance random array platform for quantitative gene expression profiling.
  4. (2006). Analysis of cell-based RNAi screens.
  5. (2007). Ashworth A
  6. (2004). Berns A
  7. (2008). Cancer proliferation gene discovery through functional genomics.
  8. (2007). Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis.
  9. (2005). Cyclindependent kinase (CDK) phosphorylation destabilizes somatic Wee1 via multiple pathways.
  10. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
  11. (1999). Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.
  12. (2007). Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation.
  13. (2004). G2 checkpoint abrogators as anticancer drugs.
  14. (2007). Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.
  15. (2006). Genome-wide functional analysis of human cell-cycle regulators.
  16. (2008). Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Invest.
  17. (2006). Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.
  18. (1993). Human wee1 maintains mitotic timing by protecting the nucleus from cytoplasmically activated Cdc2 kinase.
  19. (2008). Identification of CDK10 as an Important Determinant of Resistance to Endocrine Therapy for Breast Cancer.
  20. (2003). Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening.
  21. (2004). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.
  22. (2008). IRF4 addiction in multiple myeloma.
  23. (2008). Model-based variance-stabilizing transformation for Illumina microarray data.
  24. (2006). Mutation of the PIK3CA oncogene in human cancers.
  25. (2007). MYC amplification in breast cancer: a chromogenic in situ hybridisation study.
  26. (2006). New approaches to molecular cancer therapeutics.
  27. (2007). nuID: a universal naming scheme of oligonucleotides for illumina, affymetrix, and other microarrays.
  28. (2000). PIK3CA as an oncogene in cervical cancer.
  29. (1999). PIK3CA is implicated as an oncogene in ovarian cancer.
  30. (2005). Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity.
  31. (2008). Profiling essential genes in human mammary cells by multiplex RNAi screening.
  32. (2005). Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance.
  33. (2005). Somatic mutation and gain of copy number of PIK3CA in human breast cancer.
  34. (1999). TLR6: A novel member of an expanding toll-like receptor family.
  35. (2007). Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.